Abstract 420P
Background
Cytoreductive surgery (CRS) is a major surgery which consist of extensive tumor debulking, peritonectomy, and multiple visceral resections. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a technique in which chemotherapy is delivered in a heated solution perfused throughout the peritoneal space. In centers performing CRS-HIPEC, a significant survival benefit were observed; However, the rate of post-operative complications remains high. Acute kidney injury is a post-operative complication associated with increased morbidity and mortality and may cause delay in adjuvant chemotherapy or worse, may render the patient ineligible to receive systemic chemotherapy.
Methods
This was a retrospective cohort study, data were collected among adult patients with peritoneal carcinomatosis from colorectal, appendiceal, gastric, gynecologic cancers, and primary peritoneal mesothelioma who underwent CRS-HIPEC between Jan. 2012 and Dec. 2021 at St. Luke’s Medical Center. Data were obtained retrospectively through review of electronic medical records.
Results
A total of 162 patients who met the inclusion criteria were included in the study. Most of the patients were above 60 years old (62; 38%), females (134; 83%), had normal BMI (90; 56%), with ECOG PS 1 (160; 99%) and without comorbidities (84; 52%). Most had gynecologic malignancy (101; 63%) with high tumor grade (92; 58%) and were given with intraperitoneal cisplatin (16l 68%). Elderly patients (OR 2.70 [95% CI 0.88-8.29]; p .043 < .05); with comorbidities (OR 6.52 [95% CI 3.2-13.2]; p .001 < .05); and was given intraperitoneal Cisplatin (OR 3.99 [95% CI 1.99-8.03]; p .001 < 05) were all found to be at a higher risk for developing AKI after CRS-HIPEC.
Conclusions
The investigation noted that the elderly patients with comorbidities were found to have the highest risk of developing post-operative AKI. The most common malignancy was gynecologic cancers with high tumor grade. Cisplatin was the most common intraperitoneal chemotherapy administered and was associated with higher risk of developing acute kidney injury compared to other chemotherapy agents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06